Hudson Bay Capital Management
NVIV

Hudson Bay Capital Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Hudson Bay Capital Management’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3
Closed -$36K – 935
2017
Q4 		$36K Hold
3
– – ﹤0.01% 478
2017
Q3 		$69K Buy
+3
New +$92.2K ﹤0.01% 353

Other funds holding NVIV

ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Hudson Bay Capital Management's NVIV Position: Q1 2018 in Review

Hudson Bay Capital Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2018, closing a stake of 3 shares — an estimated $36K sold.

Hudson Bay Capital Management first reported a position in NVIV in Q3 2017 and held it in 2 quarters. The position peaked at $69K in Q3 2017. 25 funds tracked by Wall St. Rank hold NVIV as of Q1 2018.

  • Hudson Bay Capital Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2018 after selling out during the quarter.
  • Hudson Bay Capital Management sold 3 InVivo Therapeutics Holdings Corp shares in Q1 2018, an estimated $36K.
  • Hudson Bay Capital Management first reported a position in InVivo Therapeutics Holdings Corp in Q3 2017 and held it in 2 quarters.
  • Hudson Bay Capital Management's InVivo Therapeutics Holdings Corp position peaked at $69K in Q3 2017.
  • 25 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2018.

Based on Hudson Bay Capital Management's 13F filing for Q1 2018, filed 14 May 2018.